openPR Logo
Press release

Oxipit’s AI ChestEye imaging suite receives CE certification

02-04-2019 09:14 AM CET | Health & Medicine

Press release from: Oxipit

Oxipit’s AI ChestEye imaging suite receives CE certification

Leading AI-based medical imaging solutions provider Oxipit received CE certification for ChestEye radiology imaging suite. Oxipit ChestEye provides analysis and preliminary reports for 75 most common radiological findings - the largest scope of diagnosis currently available on the market - with an average area under curve metric of 93%. CE mark ensures that the software complies with medical device regulations and paves the way for commercial deployments in 32 European countries.

“The burden on radiologists has been constantly increasing. This has led to decline in quality of service for patients and bottlenecks to access good quality radiological reporting. The CE mark brings us a step closer in helping radiologists to harness the capabilities of Deep Learning in order to multiply their productivity and provide excellent service around the clock” - notes Oxipit CEO Gediminas Peksys.

ChestEye is the first AI-based full workflow medical imaging suite to be certified by a CE mark. The solution has received numerous praises from industry professionals and won multiple prizes including the 1st place at the EIT Health InnoStars Awards in 2018.

ChestEye imaging suite encompasses a fully automatic computer aided diagnosis (CAD) platform which supports 75 radiological findings. The software localizes these features on a radiograph as a heatmap. It also generates a standardized preliminary text report that incorporates all the radiologically relevant information present in a chest X-ray image.

“ChestEye currently covers over 90% of radiological cases presented to radiologists on a daily basis. It aids the specialists to detect hard-to-catch edge cases and offers a second opinion. In addition, the automatic generation of standardized medical reports significantly reduces the workload of a radiologist, allowing more time for radiogram analysis and less for case description. An internal trial showed 30% time saved per patient and reduced error rate by up to 50%” - notes Gediminas Peksys.

The Search module of ChestEye incorporates a search engine for finding similar-looking chest X-rays in a given database empowering the user to quickly find retrospective cases with similar radiological appearance. The similarity is identified by a neural network, which judges on the pathology present as well as the location of the pathology, its severity and other features.

“Most of our research data comes from tertiary level hospitals where complicated cases are analyzed and some individual images present multiple issues. The dataset represents real-life images that a medical institution encounters on a day-to-day basis, allowing our engine to achieve high precision in everyday applications” - notes Gediminas Peksys.

The suite also includes a patient prioritization solution. After receiving input of ChestEye scan results the platform prioritizes potentially unhealthy patients inviting urgent specialist attention. By automatically arranging scans by urgency it reduces time-to-treatment for time sensitive conditions such as pericardial effusion, pneumothorax, catheter or intubation malposition.

The ChestEye suite is available for deployment on premises as well as a cloud-based software. It seamlessly integrates into the workflow of any radiology department.

“Radiologists are already bombarded with too many screens and software applications. From the ground up we have built ChestEye to easily integrate into PACS (automatic image input) and RIS (automatic report output) infrastructure of a radiology department. We strongly believe that in addition to diagnostic precision, computer-aided diagnosis solutions should increase radiologist productivity and make their work less tiresome. ChestEye supports DICOM protocol for image exchange and our the team is working to incorporate HL7 and FHIR protocols in the upcoming versions of the product” - notes Gediminas Peksys.

ABOUT OXIPIT
Oxipit is a computer vision software startup specialized in medical imaging. With a team of award-winning data scientists and medical doctors, the company aims to introduce innovative Artificial Intelligence/Deep Learning breakthroughs to everyday clinical practice. Oxipit are the authors of CE certified multi-award winning ChestEye radiology imaging suite.

Oxipit
Sauletekio al. 15, LT-10224 Vilnius, Lithuania

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Oxipit’s AI ChestEye imaging suite receives CE certification here

News-ID: 1554507 • Views:

More Releases from Oxipit

Oxipit Partners With CARPL To Increase Global Reach Of AI Diagnostic Products
03-02-2023 | Health & Medicine
Oxipit
Oxipit Partners With CARPL To Increase Global Reach Of AI Diagnostic Products
At the European Congress of Radiology in Vienna Oxipit announced that its diagnostic AI solutions will be available on the CARPL platform. CARPL platform users will have access to the full Oxipit AI product portfolio: ChestLink for healthy patient report automation, Quality - for real-time quality assurance and ChestEye - for preliminary reports. The move further builds on Oxipit strategy to increase global reach of company's products. "CARPL is our
Oxipit Secures Brazilian ANVISA Clearance for ChestEye AI Suite
02-15-2023 | Health & Medicine
Oxipit
Oxipit Secures Brazilian ANVISA Clearance for ChestEye AI Suite
The regulatory approval paves the way for ChestEye deployments in the Brazilian market. The application is already cleared for use in Europe and Australia. The Brazilian Health Regulatory Agency's approval is one of Oxipit steps to increase global reach for company products. "With many future-focused healthcare organizations, LatAm market shows tremendous potential for healthcare AI applications. Oxipit products have already shown strong market traction in the region. The ANVISA certification
Oxipit Closes $4.9M Funding Round To Advance AI Autonomy in Medical Imaging
01-23-2023 | Health & Medicine
Oxipit
Oxipit Closes $4.9M Funding Round To Advance AI Autonomy in Medical Imaging
AI medical imaging company Oxipit closed a $4.9M funding round led by Taiwania Capital and Practica Capital. Angel investors also participated in this round. The funding will help Oxipit advance its development of autonomous AI medical imaging applications and support market expansion into new geographic regions, with particular focus on the United Kingdom. "2022 was a breakthrough year for the Oxipit team. In spring we introduced ChestLink - the first fully
Oxipit Introduces Quality Assurance for MSK, MG, and CT Modalities
11-21-2022 | Health & Medicine
Oxipit
Oxipit Introduces Quality Assurance for MSK, MG, and CT Modalities
AI medical imaging company Oxipit expanded its Quality product suite with quality assurance support for musculoskeletal X-rays, mammography images and lung CT scans. Previously supporting only chest X-rays, the upgraded Quality suite aims to answer all imaging department quality assurance needs with a single product. The updated Quality product will be showcased at RSNA 2022 annual meeting later this month. Oxipit Quality employs AI as the second reader for quality assurance.

All 5 Releases


More Releases for ChestEye

02-15-2023 | Health & Medicine
Oxipit
Oxipit Secures Brazilian ANVISA Clearance for ChestEye AI Suite
The regulatory approval paves the way for ChestEye deployments in the Brazilian market. The application is already cleared for use in Europe and Australia. The Brazilian Health Regulatory Agency's approval is one of Oxipit steps to increase global reach for company products. "With many future-focused healthcare organizations, LatAm market shows tremendous potential for healthcare AI applications. Oxipit products have already shown strong market traction in the region. The ANVISA certification
07-18-2022 | Health & Medicine
Oxipit
Chest experts Oxipit and contextflow team up for diagnostic quality assurance
The new partnership aims to mitigate the risk associated with missed findings in CT medical imaging studies. The collaboration will combine Oxipit's ChestEye Quality and contextflow's SEARCH Lung CT products to identify missed findings in CT scans in near-real time. ECR 2022 will offer the first preview of the combined solution, and the first installation will be deployed at Leiden University Medical Center. ChestEye Quality analyzes medical images and corresponding
11-24-2021 | Health & Medicine
Oxipit
Oxipit to offer free of charge retrospective CXR quality audit at RSNA
At the annual RSNA meeting, the AI medical imaging company will present the new ChestEye Quality AI double reading tool. To showcase vanguard ChestEye Quality capabilities, Oxipit will offer a free-of-charge quality audit for 6 months of retrospective CXR data. ChestEye Quality is already deployed in multiple medical institutions across Europe. With 229.617 images processed, the platform helped to identify 20% extra clinically relevant nodules, as well as numerous missed
05-25-2020 | Health & Medicine
Oxipit
Oxipit Receives Patent for Improved AI Lung Cancer Diagnostics
Oxipit, creators of artificial intelligence based radiology imaging suite ChestEye, announces that the European Patent Office has approved their patent application. The innovation allows efficient use of high-resolution chest X-ray images for machine learning model training and is especially relevant for improving lung nodule detection. Modern X-ray equipment produces large images with 16 Megapixel resolution being common. On the other hand, machine learning and artificial intelligence (AI) algorithms are typically optimized
03-05-2020 | Health & Medicine
Oxipit
Oxipit ChestEye secures medical device certification in Australia
The AI medical imaging company has received an Australian Register of Therapeutic Goods Class IIa medical device certificate for ChestEye AI imaging service. Medical device certification paves the way for clinical use of ChestEye in the Australian market. ChestEye imaging suite is already certified by the CE mark. Oxipit received CE certification last February, enabling clinical ChestEye deployment in 32 European countries. "Australia presents a very advanced, well developed healthcare landscape.
01-29-2020 | Health & Medicine
Oxipit
New Oxipit service to aid large scale chest X-ray screening projects
The AI medical imaging company will showcase ChestEye Negative service at Arab Health 2020 conference in Dubai. ChestEye Negative produces preliminary reports for chest X-rays with no abnormality. The service aims to reduce the workload of radiologists, especially in clinical environments, where only a fraction of all studies features an abnormality. It also significantly simplifies large-scale medical screening projects. "Large scale medical surveys - such as tuberculosis screening in migrant populations